Page 2 - நிறுவனம் உயிரியல் உரிமம் விண்ணப்பம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Search jobs 10-May-2021 Sesen Bio Reports First Quarter 2021 Financial Results and Commercial Launch Readiness Update in the US for Vicineum™ Strengthened balance sheet with $110M in cash and cash equivalents as of March 31, 2021 Company remains on track for potential approval in the US in August 2021 and in Europe in early 2022 Company to host conference call at 8am ET CAMBRIDGE, Mass. (BUSINESS WIRE) Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today reported operating results for the first quarter ended March 31, 2021. The Company’s Biologics License Application (BLA) for the Company’s lead program, Vicineum, is currently under Priority Review with the Food and Drug Administration (FDA) for the treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with a target Prescription Drug User Fee Act (PDUFA) da

Saudi arabiaUnited kingdomKingdom of saudi arabiaThomas cannellCompany phaseDrug administrationCompany marketing authorization applicationUs national cancer instituteCompany biologics license applicationExchange commissionCompany annual report on formSyneos healthChina national medical products administrationEuropean medicines agencySesen bio incHikma pharmaceuticals